Overview
- argenx reported $1.52 billion in second-quarter VYVGART product net sales, a 60% year-over-year increase and 17% rise from the prior quarter.
- The U.S. label now covers all adult generalized myasthenia gravis serotypes, which expands the pool of eligible patients and simplifies prescribing decisions for physicians.
- Operating profit rose to $494 million and diluted earnings per share reached $7.32, while cash, cash equivalents and current financial assets increased to $5.2 billion.
- The company expects registrational readouts for myositis in the third quarter of 2026 and for multifocal motor neuropathy in the fourth quarter of 2026, and it is preparing an ocular gMG filing after positive ADAPT OCULUS data.
- argenx is boosting R&D and commercial spending now to support pipeline trials and a planned 2027 subcutaneous autoinjector launch, a move that could make treatment easier for patients and drive further uptake.